Detalhe da pesquisa
1.
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
Hematol Oncol
; 40(5): 906-913, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-35946431
2.
The role of JAK inhibitors in multiple myeloma.
Clin Adv Hematol Oncol
; 17(9): 500-505, 2019 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-31549971
3.
Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.
Exp Hematol
; 111: 32-40, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35525334
4.
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Leuk Lymphoma
; 63(4): 975-983, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34818965
5.
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res
; 26(10): 2346-2353, 2020 05 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31937615
6.
Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.
Target Oncol
; 14(5): 551-561, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31473933
7.
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Leuk Res
; 81: 62-66, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31035033